Clinical Trials
11 trialsNCT07105319 2025-08-22
ROPEG
Eulji University Hospital
Phase 4 Completed
NCT04155411 2022-07-27
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Shenzhen Second People's Hospital
Phase 4 Unknown
NCT02602314 2022-01-20
SUSTRENIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 4 Unknown
NCT01243489 2019-12-20
Crescendo
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 4 Completed
NCT01578213 2019-12-03
ISAV
University of Milano Bicocca
Phase 4 Completed
NCT03216070 2017-07-13
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4 Unknown
NCT02086487 2017-03-07
NISRI
King Abdullah International Medical Research Center
Phase 4 Terminated
NCT00845221 2016-10-11
Glivec in Pediatric Chronic Myeloid Leukemia (CML)
Poitiers University Hospital
Phase 4 Completed
NCT02389920 2015-03-17
Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Samsung Medical Center
Phase 4 Unknown
NCT00461929 2009-02-13
GIST
University Health Network, Toronto
Phase 4 Terminated
NCT00390897 2008-11-27
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
PETHEMA Foundation
Phase 4 Completed